Market News & Trends
KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study
KBP Biosciences recently announced it has completed patient enrollment of BLOCK CKD (Blood Pressure in Chronic Kidney Disease), its Phase 2b study of its lead…
Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development
Alethia Biotherapeutics recently announced the US FDA has cleared its Phase 2 Investigational new drug (IND) application for AB-16B5, a potent inhibitor of the epithelial…
Catalent Announces Acquisition of Japanese Facility to Provide Local & Global Clinical Supply Solutions
Catalent recently announced a deal to acquire a clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan, from Teva-Takeda Pharmaceuticals, Nagoya Aichi,…
eGenesis Strengthens Production Capabilities With Acquisition of ICBiotec
eGenesis recently announced the acquisition of the assets and operations of ICBiotec (ICB), one of its key production partners. ICB is one of the few…
Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate
Vaxart, Inc. recently announced it has selected its lead COVID-19 vaccine candidate and has contracted with KindredBio to manufacture bulk vaccine under cGMP to complement…
CureVac´s Optimized mRNA Platform Provides Positive PreClinical Results at Low Dose for COVID-19 Vaccine Candidate
CureVac AG recently announced positive preclinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2). The data showed a…
Almac Discovery Enters Into Licensing Agreement for the Development & Commercialization of ALM301
Almac Discovery, a member of the Almac Group, recently announced an out-licensing partnership with an undisclosed biotechnology company in order to advance the development and…
Cue Biopharma Announces Strategic Research Collaboration
Cue Biopharma, Inc. recently announced it has entered into a research collaboration agreement with Dr. Michael Dustin and the University of Oxford to determine the…
Triphase Accelerator & Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial
Triphase Accelerator and Catalent recently announced interim results for Triphase Accelerator's multi-center, open-label, monotherapy study of TRPH-222 in heavily pre-treated patients with relapsed and/or refractory…
ChemoCentryx & VFMCRP Announce Topline Data from Phase 2 LUMINA-1 Trial
ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) recently announced topline data from a 46-patient Phase 2 dose-ranging trial in the orphan kidney…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….